deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL NCT00115024

EPAT: Estrogen in the Prevention of Atherosclerosis Trial

Estrogen in the Prevention of Atherosclerosis Trial

Sponsor: Mead Johnson Nutrition

Conditions Atherosclerosis Postmenopause
Interventions Micronized 17B-estradiol
Updated 5 times since 2017 Last updated: Dec 9, 2009 Started: Apr 30, 1994 Primary completion: Nov 30, 1998 Completion: Nov 30, 1998
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Atherosclerosis and Postmenopause, this trial is completed. The trial is conducted by Mead Johnson Nutrition and has accumulated 5 data snapshots since 1994. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Apr 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mead Johnson Nutrition
  • National Institute on Aging (NIA)
Data source: National Institute on Aging (NIA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations